Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Executive Summary

CDER Director tells FDA appeals board that Duchenne muscular dystrophy development could suffer if Sarepta's drug not approved.


Related Content

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Sarepta’s Aftermath: FDA Staff Still Working Together, Califf Says
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Patients Can't Rescue Sarepta's Eteplirsen
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
FDA Orphan Approval Flexibility Remains Steady As Pressure Increases


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst